SCHEMBL42601

SCHEMBL42601

CC/C(C(=O)O)=C(/CC)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 3/20 0.53
TDP1 Q9NUW8 3/20 0.44
ALDH1A1 P00352 3/20 0.44
GRIK1 P39086 2/20 0.42
GRIA4 P48058 1/20 0.42
GRIK3 Q13003 1/20 0.42
GRIK5 Q16478 1/20 0.42
THRB P10828 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
PGGT1B P53609 1/20 0.39
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
SOAT1 P35610 1/20 0.33
TSHR P16473 1/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL101165 1.00 FFAR3 (0.53) FFAR3TDP1ALDH1A1GRIK1GRIA4
SCHEMBL42603 1.00 FFAR3 (0.53) FFAR3TDP1ALDH1A1GRIK1GRIA4
SCHEMBL305428 0.96 FFAR3 (0.50) FFAR3TDP1ALDH1A1GRIK1GRIA4
SCHEMBL27684567 0.96 FFAR3 (0.50) FFAR3TDP1ALDH1A1GRIK1GRIA4
SCHEMBL2139834 0.96 FFAR3 (0.50) FFAR3TDP1ALDH1A1GRIK1GRIA4
Potassium SCHEMBL305430 0.96 FFAR3 (0.50) FFAR3TDP1ALDH1A1GRIK1GRIA4
SCHEMBL304063 0.96 FFAR3 (0.50) FFAR3TDP1ALDH1A1GRIK1GRIA4
SCHEMBL304061 0.96 FFAR3 (0.50) FFAR3TDP1ALDH1A1GRIK1GRIA4
Hydrochloric Acid SCHEMBL9622192 0.96 FFAR3 (0.50) FFAR3TDP1ALDH1A1GRIK1GRIA4
Alcohol SCHEMBL9854481 0.90 FFAR3 (0.44) FFAR3TDP1ALDH1A1GRIK1GRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1928 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630661-B2 Additives useful in 3D printing technologies Evonik Operations GmbII (DE) 2026-05-19 US claimed
EP-4558588-B1 HYDROTREATMENT PROCESS USING A SEQUENCE OF CATALYSTS WITH A CATALYST BASED ON NICKEL AND TUNGSTEN ON A SILICA-ALUMINA SUPPORT IFP ENERGIES NOW (FR) 2026-05-13 EP claimed
EP-4739724-A1 MULTI-COMPONENT RESIN SYSTEM COMPRISING AT LEAST ONE PLASTICISER, MORTAR COMPOSITION BASED ON ISOCYANATE-AMINE ADDUCTS, AND METHOD AND USE OF THE MULTI-COMPONENT RESIN SYSTEM FOR FASTENING CONSTRUCTION ELEMENTS Hilti Aktiengesellschaft (LI) 2026-05-13 EP claimed
EP-4077489-B1 POLYACRYLATE-BASED GRAFT COPOLYMER SABIC GLOBAL TECHNOLOGIES BV (NL) 2026-03-11 EP claimed
US-12440525-B2 Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2025-10-14 US claimed
EP-3833498-B1 FABRICATION OF POROUS SCAFFOLDS USING ADDITIVE MANUFACTURING WITH POTENTIAL APPLICATIONS IN BONE TISSUE ENGINEERING OHIO STATE INNOVATION FOUNDATION (US) 2025-10-01 EP claimed
WO-2025011923-A1 MULTI-COMPONENT RESIN SYSTEM COMPRISING AT LEAST ONE PLASTICISER, MORTAR COMPOSITION BASED ON ISOCYANATE-AMINE ADDUCTS, AND METHOD AND USE OF THE MULTI-COMPONENT RESIN SYSTEM FOR FASTENING CONSTRUCTION ELEMENTS HILTI AKTIENGESELLSCHAFT (LI) 2025-01-16 WO claimed
EP-4488306-A1 MULTICOMPONENT RESIN SYSTEM WITH AT LEAST ONE PLASTICIZER, MORTAR BASED ON ISOCYANATE-AMINE ADDUCTS, AND METHOD AND USE OF THE MULTICOMPONENT RESIN SYSTEM FOR FASTENING CONSTRUCTION ELEMENTS Hilti Aktiengesellschaft (LI) 2025-01-08 EP claimed
EP-3714044-B1 COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSES OTTAWA HOSPITAL RES INST (CA) 2025-01-01 EP claimed
EP-4017840-B1 FAST PREPARATION OF LOW PRIMARY AMINE CONTAINING POLYASPARTIC ESTERS AND USE OF THESE POLYASPARTIC ESTERS IN SLOW REACTIVITY POLYUREA SYSTEMS COVESTRO LLC (US) 2024-09-25 EP claimed
EP-0106443-B1 PHARMACEUTICAL ORAL-CONTROLLED RELEASE MULTIPLE-UNITS FORMULATION BENZON PHARMA A/S (DK) 1991-07-17 EP claimed
EP-0233299-B1 OPTICAL RESIN AND PROCESS FOR PREPARING THE SAME NIPPON OIL AND FATS COMPANY, LIMITED (JP) 1991-03-13 EP claimed
EP-0209621-B1 AN IMMERSION OIL FOR MICROSCOPE IDEMITSU PETROCHEMICAL CO. LTD. (JP) 1990-05-09 EP claimed
US-4791175-A Particulate hydroperoxidized poly-n-vinyl lactam, its preparation and use thereof CIBA-GEIGY CORPORATION (US) 1988-12-13 US claimed
EP-0171670-B1 FLEXIBLE CHEMICALLY TREATED FIBERS AND COATED FABRICES THEREOF PPG INDUSTRIES, INC. (US) 1988-10-05 EP claimed
US-4574080-A TIME RELEASE DRUGS A/S ALFRED BENZON (DK) 1986-03-04 US claimed
US-4572833-A COATING WITH MIXTURE OF SOLVENT, FILM-FORMING SUBSTANCE AND HYDROPHOBIC SUBSTANCE A/S ALFRED BENZON (DK) 1986-02-25 US claimed
EP-0106443-A2 Pharmaceutical oral-controlled release multiple-units formulation BENZON PHARMA A/S (DK) 1984-04-25 EP claimed
US-4218294-A MODIFIED POLYAMIDE IN ADMIXTURE WITH ACRYLATE OR METHACRYLATE MONOMER AND AN AROMATIC KETONE PHOTOINITIATOR DESIGN COTE CORP. (US) 1980-08-19 US claimed
US-4176145-A Photodegradable polymer compositions comprising blends of polymers with ketone-containing block or graft copolymers ECOPLASTICS LIMITED, 518 GORDON BAKER ROAD, WILLOWDALE, ONTARIO M2H 3B4, CANADA A CORP. OF ONTARIO 1979-11-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12440525-B2 Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses IFNG, IRF3, IFNAR1 FFAR3 4535/4885TDP1 2367/4885ALDH1A1 1771/4885
US-12630661-B2 Additives useful in 3D printing technologies HTR3D, HTR3B, HTR3C FFAR3 1355/4885TDP1 1857/4885ALDH1A1 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.